← Back to Dashboard

RVFV

Rift Valley fever phlebovirus

2
Approved Drugs
0
Phase 3
0
Phase 2
13
Preclinical
15
Total Compounds

Antiviral Compounds

AzacitidineRVFVNucleoside analog DNA methyl transferase inhibitor
Preclinical
Viral RNA pol
BortezomibRVFVProteasome inhibitor (26S subunit)
Preclinical
Human proteasome
CyclosporineRVFVCalcineurin inhibitor; allows for inhibition of T cell activation
Preclinical
Human CYPs
EmetineRVFV
Preclinical
Human ribosome
EzetimibeRVFVIntestinal cholesterol and related phytosterol absorption inhibitor
Preclinical
Human cholesterol transporter
FavipiravirRVFVViral RNA polymerase inhibitor
Approved (other)
Japan
Viral RNA pol
GalidesivirRVFVRNA-dependent RNA polymerase (RdRp) inhibitor
Preclinical
Viral RNA pol
MinocyclineRVFVBacterial protein synthesis inhibitor by binding with the 30S ribosomal subunit.
Preclinical
Human (multiple)
MonensinRVFV
Preclinical
Unknown
ObatoclaxRVFVBcl-2 family inhibitor
Preclinical
Human MCL1
OritavancinRVFVTransglycosylation; transpeptidation and cell membrane interaction/disruption inhibitor
Preclinical
Unknown
RitonavirRVFVHIV protease inhibitor
Approved (other)
JapanRussia
Unknown
SirolimusRVFVIL-2-dependent T-cell proliferation inhibitor
Preclinical
Human PTK
SuraminRVFVUnclear
Preclinical
Human (multiple)
ThioridazineRVFVPrevent viral entry
Preclinical
Human ion channel
Showing 1 to 15 of 15 results
Page 1 of 1